M

    Merck & Company Inc (MRK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $147.75
    -0.60 (-0.41%)

    Market Cap: $366.00B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    93%(37/40)
    Avg Surprise
    +11.56%
    Streak
    20 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$2.21
    Range$2.01 - $2.41
    17 analysts
    EPS Revisions
    2
    0
    7d
    1
    5
    30d
    EPS Estimate Drift
    90d ago$2.31+4.4%
    60d ago$2.31+4.4%
    30d ago$2.28+3.2%
    7d ago$2.21+0.0%
    Current$2.21
    Revenue Consensus
    $17.3B
    Range$16.9B - $17.8B
    16 analysts
    Dec 31, 2026
    EPS Consensus$2.27
    Range$2.14 - $2.38
    25 analysts
    Revenue Consensus
    $17.6B
    Range$16.9B - $17.9B
    23 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.27---
    Sep 26EST
    		-$2.21---
    Jun 26
    		$-0.13$-0.26+50.00%Beat-106.1%
    Mar 26
    		$-1.28$-1.47+12.93%Beat-157.7%
    Dec 25
    		$2.04$2.01+1.49%Beat+18.6%
    Sep 25
    		$2.58$2.35+9.79%Beat+64.3%
    Jun 25
    		$2.13$2.03+4.93%Beat-6.6%
    Mar 25
    		$2.22$2.14+3.74%Beat+7.2%
    Dec 24
    		$1.72$1.67+2.99%Beat+5633.3%
    Sep 24
    		$1.57$1.57+0.00%Beat-26.3%
    Jun 24
    		$2.28$2.14+6.54%Beat+210.7%
    Mar 24
    		$2.07$1.92+7.81%Beat+47.9%
    Dec 23
    		$0.03N/A+127.27%Beat-98.1%
    Sep 23
    		$2.13$1.95+9.23%Beat+15.1%
    Jun 23
    		$-2.06$-2.18+5.50%Beat-210.2%
    Mar 23
    		$1.40$1.34+4.48%Beat-34.6%
    Dec 22
    		$1.62$1.54+5.19%Beat-10.0%
    Sep 22
    		$1.85$1.71+8.19%Beat+5.7%
    Jun 22
    		$1.87$1.71+9.36%Beat+42.7%
    Mar 22
    		$2.14$1.83+16.94%Beat+52.9%
    Dec 21
    		$1.80$1.52+18.42%Beat+36.4%
    Sep 21
    		$1.75$1.55+12.90%Beat+0.6%
    Jun 21
    		$1.31$1.35-2.96%Miss-4.4%
    Mar 21
    		$1.40$1.61-13.04%Miss-6.7%
    Dec 20
    		$1.32$1.39-5.04%Miss+13.8%
    Sep 20
    		$1.74$1.43+21.68%Beat+15.2%
    Jun 20
    		$1.37$1.09+25.69%Beat+5.4%
    Mar 20
    		$1.50$1.34+11.94%Beat+23.0%
    Dec 19
    		$1.16$1.15+0.87%Beat+11.5%
    Sep 19
    		$1.51$1.24+21.77%Beat+26.9%
    Jun 19
    		$1.30$1.16+12.07%Beat+22.6%
    Mar 19
    		$1.22$1.05+16.19%Beat+16.2%
    Dec 18
    		$1.04$1.03+0.97%Beat+6.1%
    Sep 18
    		$1.19$1.14+4.39%Beat+7.2%
    Jun 18
    		$1.06$1.03+2.91%Beat+5.0%
    Mar 18
    		$1.05$1.00+5.00%Beat+19.3%
    Dec 17
    		$0.98$0.94+4.26%Beat+10.1%
    Sep 17
    		$1.11$1.03+7.77%Beat+3.7%
    Jun 17
    		$1.01$0.87+16.09%Beat-
    Mar 17
    		$0.88$0.83+6.02%Beat-
    Dec 16
    		$0.89$0.89+0.00%Beat-
    Sep 16
    		$1.07$0.99+8.08%Beat-

    Dividends

    Dividend Metrics

    Yield2.27%
    Annual/Share$3.36
    Payout Ratio41.52%
    Frequency4
    Pay MonthsJan, Apr, Jul, Oct

    Growth

    3Y CAGR+5.42%
    5Y CAGR+5.75%
    View MRK's full dividend history

    Key Metrics

    Valuation
    P/E Ratio46.03EV/EBITDA28.86x
    Price/FCF22.69xFCF Yield4.41%
    Profitability
    Profit Margin4.77%Operating Margin-0.24%
    ROE6.96%ROIC4.03%
    Financial Health
    Debt/Equity1.29xInterest Coverage139.52x
    Current Ratio1.32xQuick Ratio1.10x
    Trading Statistics
    Beta0.21Avg Volume11.20M
    52-Week High$156.9252-Week Low$75.81

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$149.48
    SMA 20$140.48
    SMA 50$132.13
    SMA 200$116.39
    EMA 10$147.56
    EMA 20$142.76
    EMA 50$134.07
    EMA 200$117.09

    MACD

    Line: 6.11Signal: 5.68Hist: 0.42

    ADX

    ADX: 41.9+DI: 34.9-DI: 15.0

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down24.0
    PSAR$156.92

    Bollinger Bands

    Upper Band$161.03
    Lower Band$119.93
    %B Position2926%(Upper)
    Band Width0.68

    RSI (14-Day)

    Neutral
    61.5

    Momentum Oscillators

    Stoch %K70.3
    Stoch %D78.0
    Williams %R-32.8
    ROC (10d)8.7%
    Momentum11.78
    CCI (20d)51.2
    MFI (14d)60.7

    Volatility Measures

    ATR (14d)$4.25(2.9%)
    StdDev (20d)10.28
    Hist Vol50.9%(High)

    Volume Flow

    VWAP$147.47
    OBV278.7M
    AD Line-5.4B
    CMF (20d)0.173

    Volume Metrics

    Avg Vol (20d)11.2M
    Vol Ratio1.0x
    VWMA (20d)$143.17

    Pivot Points

    R3$152.91
    R2$150.96
    R1$149.66
    Pivot Point$147.70
    S1$146.40
    S2$144.44
    S3$143.14

    Advanced Oscillators

    TSI36.63
    Ultimate Osc58.7
    KST149.41

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$16.61B$16.29B$16.40B$17.28B$15.81B$15.53B$15.62B$16.66B$16.11B$15.78B$14.63B$15.96B
    Cost of Revenue$4.39B$4.20B$5.55B$3.85B$3.56B$3.42B$3.83B$4.08B$3.75B$3.54B$3.91B$4.26B
    Gross Profit$12.21B$12.09B$10.85B$13.42B$12.25B$12.11B$11.80B$12.58B$12.37B$12.23B$10.72B$11.70B
    Operating Expenses$12.80B$15.49B$7.00B$6.91B$7.26B$6.24B$7.50B$8.65B$6.32B$6.60B$12.69B$5.95B
    R&D$9.74B$12.59B$3.89B$4.23B$4.05B$3.62B$4.58B$5.86B$3.50B$3.99B$9.63B$3.31B
    SG&A$2.90B$2.70B$2.90B$2.63B$2.65B$2.55B$2.86B$2.73B$2.74B$2.48B$2.80B$2.52B
    Operating Income$-584,000,000$-3,396,000,000$3.85B$6.51B$4.99B$5.87B$4.30B$3.93B$6.05B$5.64B$-1,967,000,000$5.75B
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$99.00M$138.00M$431.00M$0$0$0$129.00M$0$42.00M$0$79.00M$126.00M
    Income Before Tax$-683,000,000$-3,534,000,000$3.42B$6.75B$5.00B$5.90B$4.17B$4.09B$6.01B$5.67B$-2,046,000,000$5.62B
    Income Tax Expense$654.00M$709.00M$457.00M$958.00M$571.00M$818.00M$426.00M$929.00M$545.00M$903.00M$-820,000,000$870.00M
    Net Income$-1,337,000,000$-4,243,000,000$2.96B$5.79B$4.43B$5.08B$3.74B$3.16B$5.46B$4.77B$-1,226,000,000$4.75B
    EBITDA$900.00M$-2,022,000,000$5.89B$7.90B$6.12B$7.00B$5.37B$5.28B$7.14B$6.65B$-1,082,000,000$6.63B
    EBIT$-683,000,000$-3,534,000,000$3.42B$6.75B$5.00B$5.90B$4.17B$4.09B$6.01B$5.67B$-2,046,000,000$5.62B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    Pfizer: The 6% Yield Hiding Behind a Post-Pandemic Hangover

    Pfizer trades at 9.6x forward earnings with 6.3% yield; non-COVID portfolio grew 6% operationally in 2025, but market still prices post-pandemic discount GAAP payout ratio of 98.8% is misleading; on adjusted EPS of $3.22, actual payout is 53%. The $4.4B Seagen impairment distorts GAAP picture Metsera obesity pipeline (Phase 2b: 12.3% weight loss, monthly dosing) is unpriced optionality at current multiples; ten Phase 3 trials launch 2026 Morningstar cut fair value from $34 to $32 post-Q4; Stock Rover FV $34.57. Blended upside of 13-16% before dividends in base case Quality Score 85/100, Piotroski 7, Beneish M-Score -2.38. ROIC-WACC spread positive at +190 bps. Balance sheet is not the risk here Five explicit risks quantified: GAAP payout tightness, $1.5B LOE headwind, negative revision momentum, Metsera execution risk, policy headwinds Conditional BUY for income/value accounts with staged sizing at 0.5-1.0%; trim at $33-36; invalidation on dividend cut or two sub-$0.65 adj EPS quarters

    Unknown Author
    •
    2/12/26
    •
    150
    Income Investing
    value investing
    Also mentions:
    MRK
    BMY
    GILD
    ABBV

    Ultra ZEUS: The Ultimate "Magic Money Machine" (22% Target Return with Ultra Low Volatility) For My Family's Needs For 2026

    GNG Research is built around a dream to democratize financial information and to create investing tools and automated systems that allow ANYONE to achieve their financial dreams. The Medallion Fund from Renaissance Tech shows the power of a well-designed algo fund, and Connor and Glenn are hard at work building tools that will allow for superhuman portfolio optimization (like 1.7% peak declines) To support our incredible development team (Sleep is still a thing! 😉😂), we plan to expand to 9 or 10 people in 2026, at a cost of around $600K. To fund the conservative $600K it will cost to build out GNG's team and tools, we'll have to rely on the ZEUS LEGACY Family Charity Hedge Fund, which protects 17 people (and GNG). Our 1 million Monte Carlo simulations at the end of 2025 indicate that the S&P is most likely to experience 16% gains in 2026 (similar to 2025), but with 20% annual volatility (2 corrections most likely). In order to generate a conservative $500K in annual profits, we need an 8.65% gain in the ZEUS portfolio BUT historically we achieve 50% of fundamentally justified returns (so we need to shoot for 20%, $1 million). Ultra ZEUS 2026 is the strangest-looking portfolio I've ever built, but after 30 hours of R&D and five layers of double-checking the math, it's 99.9% optimal for my family's (and GNG's) needs for 2026. This 2.7% yielding portfolio has 20% growth, a forward PE of 16 (PEG of 1.1), and has profitability (quality) that's 30% to 70% better than the market. It captures 71% of the market's upside and -4% of the downside.

    Unknown Author
    •
    1/6/26
    •
    1,438
    2026 Stock Picks
    2026 probable returns
    value investing
    Income, Value
    Also mentions:
    MRK
    MELI
    EPD
    CTA
    SQQQ

    Government Contracts

    Gov Obligations (TTM)
    $5.15M
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    -96.7%
    Active Awards
    49
    New Awards (TTM)
    38
    Avg Remaining Term
    93.6 mo

    Top agency: Department of Health and Human Services at 75.3% of trailing twelve month obligations across 6 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0282Department of Veterans AffairsDepartment of Veterans Affairs$342254Jun 1, 2026
    140F1G25P0056Department of the InteriorU.S. Fish and Wildlife Service$297003Aug 15, 2025
    140R3025P0053Department of the InteriorBureau of Reclamation$127600Sep 18, 2025
    140G0326P0069Department of the InteriorU.S. Geological Survey$122636Mar 16, 2026
    36C26126N0291Department of Veterans AffairsDepartment of Veterans Affairs$96218Jan 13, 2026
    140R4025P0100Department of the InteriorBureau of Reclamation$90955Sep 16, 2025
    140R2026P0003Department of the InteriorBureau of Reclamation$73669Mar 12, 2026
    36C26026F0280Department of Veterans AffairsDepartment of Veterans Affairs$42782May 4, 2026
    140F1G26P0027Department of the InteriorU.S. Fish and Wildlife Service$25967Jul 27, 2026
    140F1G25P0078Department of the InteriorU.S. Fish and Wildlife Service$24818Sep 10, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    North Star Asset Management Inc. Acquires New Shares in Amgen Inc. $AMGN

    North Star Asset Management Inc. has acquired a new position in Amgen Inc., purchasing 10,471 shares valued at approximately $3.79 million. Other institutional investors like BlackRock Inc., State Street Corp, and Capital World Investors also significantly increased their stakes in Amgen. Despite some mixed analyst ratings, Amgen reported strong Q2 earnings, beating revenue and EPS estimates, and announced a quarterly dividend of $2.52 per share.

    MarketBeat•8/29/26•
    Neutral

    Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement

    Eli Lilly and Co (LLY) stock opened down 3.57% on August 26, primarily due to investor profit-taking after a recent surge and growing concerns over reimbursement for obesity treatments. Despite this short-term pressure, the company maintains a strong competitive position and a positive long-term growth outlook in the cardiometabolic space. Key risks include employer coverage pushback, commercial hurdles for oral GLP-1 drugs, and European reimbursement pressures.

    TradingKey•8/26/26•
    Somewhat-Bearish

    Merck Stock Hits New 52-Week High: What's Driving the Rally?

    Merck's stock recently reached a new 52-week high due to renewed investor confidence stemming from positive clinical trial data for its personalized cancer therapy with Moderna, strong pipeline progress, new product launches, and strategic acquisitions. These developments are expected to drive future growth and mitigate the impact of Keytruda's patent expiration in 2028. The company's management expressed confidence in its diversified portfolio and positioning for sustainable growth.

    TradingView•8/26/26•
    Bullish

    Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed

    The FDA has extended its review of Capricor Therapeutics' Duchenne muscular dystrophy cell therapy, while Merck and Moderna announced positive Phase 3 results for their mRNA-based cancer vaccine. Trump has nominated Heidi Overton as the new FDA commissioner, whose appointment is expected to impact psychedelics and new pain medications, but potentially negatively affect vaccines. Meanwhile, the oral obesity market is heating up with fierce competition between Novo Nordisk and Eli Lilly.

    BioSpace•8/26/26•
    Bullish

    Occidental Asset Management LLC Buys 11,002 Shares of Merck & Co., Inc. $MRK

    Occidental Asset Management LLC increased its stake in Merck & Co., Inc. by 24% in the second quarter, purchasing an additional 11,002 shares to bring its total holdings to 56,777 shares valued at approximately $7.3 million. Institutional investors collectively own 76.07% of Merck, while analysts maintain a "Moderate Buy" consensus with an average price target of $147.60. Despite recent insider selling, Merck's shares are trading near their 52-week high following better-than-expected quarterly earnings and revenue growth.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    Frequently Asked Questions About MRK

    What is MRK's current dividend yield?
    Merck & Company Inc (MRK) has a current dividend yield of 2.27%.
    Does MRK pay dividends?
    Yes, Merck & Company Inc pays dividends with a current yield of 2.27%.
    What is MRK's P/E ratio?
    Merck & Company Inc has a price-to-earnings (P/E) ratio of 46.03.
    What is MRK's market cap?
    Merck & Company Inc (MRK) has a market capitalization of $366.00B with a current stock price of $147.75.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In